Current replication
Spearman rank correlation
Not measuredNo current measurement is available in this registry.
Research study · 2025
Patient preferences and willingness-to-pay for therapy in generalized myasthenia gravis: a large-scale discrete choice experiment in China
Explore the published experiment and its available replication evidence.
Read the paper ↗01 / Human finding
What the study found
A reviewed summary is not available in this registry. Consult the published paper for the original finding.
Answer-key review: Not reviewed
02 / Experiment design
Who chose, and what varied
- Country
- China
- Human respondents
- Not recorded
- Attributes
- 8
- Task
- discrete choice
03 / Synthetic replication
Registry replication results
Paper-era reference
2023 CLM mean Spearman ρ
Not measuredHistorical results use their original estimator and reference. They are not a matched comparison with the current run.
Detailed replication evidence · 2026-11-02
Right direction on 13 of 14 significant effects, close ranking (ρ = 0.90); sizes not comparable (the paper reports logit coefficients).
Use it to screen and rank which attributes move choice; sizes need the paper's respondent data, and confirm the reversed effect with people.
- direction
- holds
- rank
- holds
- size
- not comparable
Supported uses
- Screening which attributes move choice, and in which direction.
- Ranking attributes and levels by how strongly they move choice.
Limits to keep in view
- Effect sizes in the paper's units; only direction, rank and shape are compared.
Effects on a common scale
Human effects: logit coefficient. Synthetic effects are multiplied by the record’s calibration factor, k = 2.5257. Calibration aligns magnitude; it does not establish agreement in unadjusted effect sizes.
| Attribute / level | Human | Human 95% half-width | Calibrated synthetic |
|---|---|---|---|
| Onset time of action (Time to improvement of gMG symptoms from treatment initiation): > 2 weeks | 0.157 | Not measured | -0.114 |
| Administration route: Oral | 0.241 | Not measured | 0.279 |
| Administration route: Subcutaneous injection (injection time 20 min) | 0.108 | Not measured | 0.102 |
| Administration route: Intravenous injection (infusion time ≥60 min) (reference) | 0.000 | Not measured | 0.000 |
| Treatment frequency: Once daily | 0.284 | Not measured | 0.288 |
| Treatment frequency: Once weekly | 0.109 | Not measured | 0.204 |
| Treatment frequency: Once biweekly | 0.058 | Not measured | 0.162 |
| Treatment frequency: Once every-6-month | 0.396 | Not measured | 0.335 |
| Treatment frequency: 2–3 times daily (reference) | 0.000 | Not measured | 0.000 |
| Risk of metabolic diseases (Metabolic diseases include weight gain, central obesity, increased blood pressure, elevated blood glucose, etc.): Low | 0.477 | Not measured | 0.341 |
| Risk of metabolic diseases (Metabolic diseases include weight gain, central obesity, increased blood pressure, elevated blood glucose, etc.): Moderate | 0.366 | Not measured | 0.232 |
| Risk of metabolic diseases (Metabolic diseases include weight gain, central obesity, increased blood pressure, elevated blood glucose, etc.): High (reference) | 0.000 | Not measured | 0.000 |
| Risk of Infection (Infection include upper respiratory tract infection, meningococcal infection, urinary tract infection, etc.): Low | 0.419 | Not measured | 0.502 |
| Risk of Infection (Infection include upper respiratory tract infection, meningococcal infection, urinary tract infection, etc.): Moderate | 0.308 | Not measured | 0.419 |
| Risk of Infection (Infection include upper respiratory tract infection, meningococcal infection, urinary tract infection, etc.): High (reference) | 0.000 | Not measured | 0.000 |
| Risk of myelosuppression (Myelosuppression includes anemia, leukopenia, thrombocytopenia, etc.): Low | 0.565 | Not measured | 0.504 |
| Risk of myelosuppression (Myelosuppression includes anemia, leukopenia, thrombocytopenia, etc.): Moderate | 0.405 | Not measured | 0.376 |
| Risk of myelosuppression (Myelosuppression includes anemia, leukopenia, thrombocytopenia, etc.): High (reference) | 0.000 | Not measured | 0.000 |
| Risk of liver and kidney function impairment: Low | 0.463 | Not measured | 0.549 |
| Risk of liver and kidney function impairment: Moderate | 0.343 | Not measured | 0.292 |
| Risk of liver and kidney function impairment: High (reference) | 0.000 | Not measured | 0.000 |
| Onset time of action (Time to improvement of gMG symptoms from treatment initiation): ≤2 weeks (reference) | 0.000 | Not measured | 0.000 |
Subgroups · screen, not a result
Split by age: significance not reported between the groups, so there is nothing to compare
screen, not a result. Each row is the old over 50 group’s effect minus the young 18 50 group’s, human in logit, simulated on the simulation’s own scale, so compare direction, not size. A Jev fast-small screen makes no comparison claim.
- Sign agreement
- –
- 95% interval
- no interval
- Shuffle null
- –
- Shape ρ
- -0.43, null p 0.91
- Scale ratio
- 1.38×
| Group | Simulated n | People n | ρ vs paper |
|---|---|---|---|
| old over 50 | 213 | not given | 0.71 |
| young 18 50 | 137 | not given | 0.79 |
| Attribute / level | People Δ (95%) | Significant | Simulated Δ (own scale) | Direction |
|---|---|---|---|---|
| Treatment frequency: Once daily | +0.19 no interval | not reported | -0.03 ±0.10 | not reported |
| Treatment frequency: Once every-6-month | +0.07 no interval | not reported | +0.07 ±0.10 | not reported |
| Risk of myelosuppression (Myelosuppression includes anemia, leukopenia, thrombocytopenia, etc.): Low | +0.27 no interval | not reported | +0.06 ±0.08 | not reported |
| Risk of myelosuppression (Myelosuppression includes anemia, leukopenia, thrombocytopenia, etc.): Moderate | +0.05 no interval | not reported | +0.02 ±0.08 | not reported |
| Risk of metabolic diseases (Metabolic diseases include weight gain, central obesity, increased blood pressure, elevated blood glucose, etc.): Moderate | +0.12 no interval | not reported | -0.08 ±0.08 | not reported |
| Treatment frequency: Once weekly | -0.04 no interval | not reported | +0.07 ±0.08 | not reported |
| Administration route: Subcutaneous injection (injection time 20 min) | -0.03 no interval | not reported | -0.00 ±0.07 | not reported |
04 / Evidence and limitations
Follow the evidence
Missing results mean unmeasured, not zero agreement.
- missing parent paper url
- missing canonical pdf
- missing historic score
- missing resolved wandb run